GLP-1 Weight-Loss Drugs May Elevate Bone and Tendon Injury Risk, Study Finds
A large study suggests GLP-1 receptor agonists like Ozempic may increase the risk of bone and tendon injuries, with osteoporosis and gout cited as examples, highlighting potential long-term safety trade-offs for these weight-loss/diabetes medications.